Drug pipeline
Explore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Monocarboxylate transporter 2 (MCT2), encoded by the SLC16A7 gene, is a proton-coupled symporter that mediates the rapid, bidirectional transport of monocarboxylates such as L-lactate, pyruvate, and ketone bodies across the plasma membrane. Compared to other members of the monocarboxylate transporter family (such as MCT1 and MCT4), MCT2 exhibits a significantly higher affinity for its substrates, particularly pyruvate and lactate. It is predominantly expressed in the central nervous system, specifically in neurons, where it plays a critical role in the astrocyte-neuron lactate shuttle by facilitating lactate uptake for oxidative metabolism. Additionally, MCT2 is expressed in other metabolically active tissues, including the testis, kidney, and liver.
In pathological contexts, MCT2 is frequently overexpressed in various malignancies, including prostate cancer, colorectal cancer, glioblastoma, and breast cancer, where it supports the metabolic reprogramming of tumor cells (the Warburg effect) and helps regulate intracellular pH. Consequently, MCT2 has emerged as a promising therapeutic target in oncology. Inhibiting MCT2 disrupts lactate and pyruvate transport, leading to intracellular acidification, glycolytic inhibition, and metabolic starvation of cancer cells. Several small-molecule inhibitors, such as the dual MCT1/MCT2 inhibitors AZD3965 and AR-C155858, have been developed to target this pathway, with AZD3965 undergoing clinical evaluation. However, therapeutic challenges include potential toxicities in healthy tissues with high metabolic demands (such as the brain, retina, and heart) and compensatory upregulation of other transporter isoforms like MCT4, which can confer resistance to MCT2 inhibition.
Inhibition of proton-coupled monocarboxylate transport, blocking the influx and efflux of lactate, pyruvate, and ketone bodies across the cell membrane, leading to intracellular acidification, disruption of glycolysis, and metabolic starvation of cancer cells.
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Monocarboxylate transporter 2 (MCT2).